www.fdanews.com/articles/127580-antisoma-rsquo-s-as1413-gains-fda-fast-track-status-for-myeloid-leukemia

Antisoma’s AS1413 Gains FDA Fast Track Status for Myeloid Leukemia

June 3, 2010

Cancer drug developer Antisoma Thursday announced that the FDA has granted Fast Track designation to the Company’s novel DNA intercalator, AS1413 (amonafide L-malate), for the treatment of secondary acute myeloid leukemia.
MarketWatch